Shots:

• The companies collaborated to acquire V-Go for $10M up front & an additional sales-based milestones along with the cost of certain inventory. The transaction is expected to close in May 2022
• Following the acquisition of VGo, MannKind will be able to expand its portfolio, reinforce its commitment to offer new dietary diabetes & positioning its endocrine business for additional growth. The agreement is part of Zealand’s strategy to seek partners for commercial and late-stage assets while focusing on R&D
• V-Go is a wearable insulin delivery device that helps to manage blood sugar in everyday situations. V-Go is a patch-like device that avoids the need for several daily doses and is designed to be patient-friendly

Ref: Globenewswire | Image: MannKind